Ketamine-assisted psychotherapy for the treatment of persistent depression in abstinent opioid users

Date Added
December 7th, 2021
PRO Number
Pro00115696
Researcher
Eric Dobson

List of Studies

Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.

Institution
MUSC
Recruitment Contact
Eric Dobson
843-729-1445
dobsoner@musc.edu

Integrated Treatment for Opioid Use Disorder and Posttraumatic Stress Disorder

Date Added
October 8th, 2021
PRO Number
Pro00114390
Researcher
Tanya Saraiya

List of Studies

Keywords
Psychiatry
Summary

We are seeking participants who have used or currently use opioids, are between the ages of 18-65, and a have experienced a traumatic event. A traumatic event is something incredibly frightening, such as physical assault, domestic violence, or sexual assault. We will interview participants for their preferences in treatment for 60-90 minutes. Interviews are confidential. Participants will be compensated $25 for their time.

Institution
MUSC
Recruitment Contact
Tanya Saraiya
8438762374
saraiya@musc.edu

Gabapentin for Restoring GABA/glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders: A Randomized, Double-blind, Placebo-controlled, Parallel-group, MRI Study

Date Added
August 3rd, 2021
PRO Number
Pro00112593
Researcher
James Prisciandaro

List of Studies


Keywords
Depression, Mental Health, Psychiatry, Substance Use
Summary

This research study evaluates the effects of anFDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

Institution
MUSC
Recruitment Contact
Sara Hix
843-792-0572
hixs@musc.edu

Integrated Treatment for Women with Co-Occurring Opioid Use Disorder and Posttraumatic Stress Disorder

Date Added
July 16th, 2021
PRO Number
Pro00111570
Researcher
Tanya Saraiya

List of Studies

Keywords
Psychiatry, Women's Health
Summary

We are seeking women who have used or currently use opioids, are between the ages of 18-65, and a have experienced a traumatic event. A traumatic event is something incredibly frightening, such as physical assault, domestic violence, or sexual assault. We will interview participants for their preferences in treatment for 60-90 minutes. Interviews are confidential. Participants will be compensated $25 for their time.

Institution
MUSC
Recruitment Contact
Tanya Saraiya
347 961 8252
saraiya@musc.edu

Gender and Sex Hormone Influences on Cannabis Use Disorder Remission

Date Added
June 1st, 2021
PRO Number
Pro00110801
Researcher
Rachel Tomko

List of Studies


Keywords
Hormones, Mental Health, Psychiatry, Substance Use
Summary

Adults (ages 18+) who would like to reduce their cannabis use (N=224) will be enrolled in an 8-week treatment program. All participants will receive counseling (1 goals session with a therapist followed by 7 weekly computerized cognitive-behavioral therapy sessions). Detailed cannabis assessments (biological and self-report) will be conducted throughout treatment and at 1-, 2-, and 3-months post-treatment completion. Daily electronic diaries will be administered via text message to record detailed logs of cannabis use quantity and frequency. Salivary samples will be collected (and video observed) daily throughout treatment to analyze for progesterone.

Institution
MUSC
Recruitment Contact
Kevin Branson
843-792-9257
bransonk@musc.edu

Maternal Mental Health Screening and Referral to Treatment in South Carolina Pee Dee Region Healthy Start Programs

Date Added
June 1st, 2021
PRO Number
Pro00110639
Researcher
Constance Guille

List of Studies


Keywords
Mental Health, Pregnancy, Psychiatry, Women's Health
Summary

This study involves partnering with Healthy Start Programs in the SC Pee Dee region to evaluate Listening to Women (LTW), a text message based mental health and substance use screening and referral to treatment program, compared to usual care (Screening, Brief Intervention, and Referral to Treatment (SBIRT)), among pregnant and postpartum women. The study also involves doing interviews and focus groups (group discussions) with women in the Healthy Start programs, community health workers (CHWs), and key local and state stakeholders.

Institution
MUSC
Recruitment Contact
Edie Douglas
8437920403
douglaed@musc.edu

Cytochrome P450 and Subjective Cannabis Response in Youth Cannabis Use Disorder

Date Added
March 2nd, 2021
PRO Number
Pro00107842
Researcher
Rachel Tomko

List of Studies


Keywords
Adolescents, Genetics, Psychiatry, Substance Use
Summary

Eligible adolescents and emerging adults (ages 12-25) who have used cannabis in the past year will attend 1-2 laboratory visits. They will complete a series of interviews and self-report measures, including assessment of cannabis quantity and frequency, subjective effects of cannabis, and problems due to cannabis use. They will provide a urine sample for analysis of a THC metabolite and they will provide a blood sample for analysis of genes related to cytochrome P450 enzyme activity, which are thought to be associated with metabolism of THC.

Institution
MUSC
Recruitment Contact
Youth Collaborative
843-792-9257
youth@musc.edu

PTSD Treatment and Emotion Regulation Skills Training for Veterans with Military Sexual Trauma

Date Added
March 2nd, 2021
PRO Number
Pro00107912
Researcher
Wendy Muzzy

List of Studies